Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
In a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated ...
Apr 5, 2024
0
0